A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Clinical worsening also occurred less frequently with treprostinil ...

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider Jeffrey J. Swigris, ...

Kevin Walton, Baseimmune CEO. IPF is a progressive and life-threatening condition marked by aberrant wound healing, ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

St. Luke’s University Health Network has been designated as a Care Center within the Pulmonary Fibrosis Foundation’s nationally recognized Care Center Network, expanding access to specialized care ...

A brief course of morphine provided some relief for patients with cough related to idiopathic pulmonary fibrosis (IPF) in a small, phase II double-blind crossover trial. Two weeks of low-dose ...